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Abstract
Background: There is limited research on why some individuals who have undergone predictive genetic testing
for Lynch syndrome do not adhere to screening recommendations. This study aimed to explore qualitatively how
Lynch syndrome non-carriers and carriers translate genetic risk information and advice to decisions about risk
managment behaviours in the Australian healthcare system.
Methods: Participants of the Australasian Colorectal Cancer Family Registry who had undergone predictive genetic
testing for Lynch syndrome were interviewed on their risk management behaviours. Transcripts were analysed
thematically using a comparative coding analysis.
Results: Thirty-three people were interviewed. Of the non-carriers (n = 16), 2 reported having apparently unnecessary
colonoscopies, and 6 were unsure about what population-based colorectal cancer screening entails. Of the
carriers (n = 17), 2 reported they had not had regular colonoscopies, and spoke about their discomfort with the
screening process and a lack of faith in the procedure’s ability to reduce their risk of developing colorectal cancer. Of
the female carriers (n = 9), 2 could not recall being informed about the associated risk of gynaecological cancers.
Conclusion: Non-carriers and female carriers of Lynch syndrome could benefit from further clarity and advice about
appropriate risk management options. For those carriers who did not adhere to colonoscopy screening, a lack of faith
in both genetic test results and screening were evident. It is essential that consistent advice is offered to both carriers
and non-carriers of Lynch syndrome.
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Background
There are various genetic syndromes related to colorectal
cancer (CRC). One of the most common is Lynch
syndrome (LS), which accounts for 1 – 3% of all CRCs [1].
LS develops as a result of an autosomal dominant germline
mutation in one of a group of DNA mismatch repair
(MMR) genes, notably the following four: MLH1, MSH2,
MSH6 and PMS2. When a MMR gene mutation is identi-
fied in an individual with CRC (i.e. a carrier), predictive
genetic testing is then available to first degree relatives.
Without preventive measures, the development of CRC
amongst LS affected individuals is estimated at a lifetime
risk of 10 – 74%, depending on sex and the MMR gene
mutated [2, 3]. Female carriers are also at an increased risk
of gynaecological cancers (GC), with an estimated lifetime
risk for endometrial cancer of 14 – 71%, and 4 – 20% for
ovarian cancer [2, 3]. Individuals with a pathogenic
mutation for LS also have an increased risk of gastric
cancers (3 – 13%) and other extra-colonic malignancies
such as brain tumours and skin cancer [2–5] . Routine
screening in the form of annual or biennial colonoscopy
from age 25 (or 5 years earlier than the youngest CRC
diagnosis in the family) is the standard recommendation
for individuals with LS in Australia [6, 7]. Regular colon-
oscopy screening has been shown to reduce the risk of
developing CRC [8] and delay the age of onset by more
than 10 years [9], with CRC mortality rates reduced by up
to 65% among LS individuals [7]. Colorectal surgical inter-
vention is generally not recommended to individuals with
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LS until an index CRC develops. Screening recommenda-
tions are less clearly established for associated GC, with a
suggestion that women should consider starting annual
pelvic ultrasounds with endometrial sampling between 30
and 35 years of age for the detection of endometrial
cancer, however the evidence of benefit is weak [10].
To date, no benefit has been shown for ovarian cancer
screening [11]. The only effective intervention to reduce
the risk of GC in women is prophylactic hysterectomy and
bilateral salphingo-oophorectomy (BSO) from age 40 years,
or once they have completed childbearing [12, 13].
An individual who tests negatively for a known family
MMR gene mutation (i.e. a non-carrier) is considered to be
at population risk for all LS-associated cancers, and is there-
fore advised to follow population-based CRC screening
recommendations [14]. Recommended population-based
CRC screening in Australia is a non-invasive immuno-
chemical faecal occult blood test (FOBT) every 1 – 2
years, commencing at age 50 [15]. As part of the National
Bowel Cancer Screening Program, a free FOBT kit is cur-
rently sent in the mail to all Australians turning 50, 55, 60,
65, 70 and 74 [16]. Given the risk of adverse event such as
perforation [17, 18], and associated cost of the procedure,
screening colonoscopies are not recommended to those at
population risk of CRC [19], and are generally only used to
investigate a positive FOBT result (i.e. blood is detected).
Previous research has linked personal genetic mutation
results with the adoption of more appropriate screening
intervals, such that carriers increase screening frequency
and non-carriers decrease screening intervals if screening
previously at a rate higher than recommended [20–26].
One of the first studies to evaluate long-term follow-up
for individuals who have been tested for LS demonstrated
through 3-year longitudinal data that the majority of those
who received genetic risk information screened appropri-
ately according to their carrier status [27]. Of 19 carriers
in the study, all had a colonoscopy within 3 years, the
majority of whom screened in the first 12 months. Of
54 non-carriers, only 7% had a colonoscopy within the
2 years before the 3-year follow-up. Nine of 13 female
carriers (69%) reported having had a pelvic ultrasound
in the previous 2 years, including endometrial sampling in
seven cases. As noted in many previous studies, psycho-
logical distress returned to baseline levels within 12 months
of receiving results and was maintained for 2 years in
carriers. For non-carriers, levels of psychological dis-
tress steadily decreased over 3 years. A recent study by
Esplen et al. [28] also found that in the long term indi-
viduals tend to adapt to their genetic test result, with
self-reported screening being much higher in carriers
than non-carriers. Studies to date have been unable to
explain why some non-carriers continue to have un-
necessary invasive screening when they are considered
to be at population risk of CRC, nor do they report on
women’s uptake of measures to address their increased
risk of GC.
Given how little is known about why some individuals
who have undergone predictive genetic testing for LS do
not adhere to screening recommendations, this study
employed a qualitative methodology with a population-
based sample to explore how LS carrier status trans-
lates to risk management behaviour. Specific research
interests included why some non-carriers continue to have
unnecessary invasive screening, and why some carriers do
not follow screening recommendations.
Methods
Recruitment
The Australasian Colorectal Cancer Family Registry
(ACCFR) studies a large number of population-based
Victorian residents recently diagnosed with CRC (within
2 years) and attendees to family cancer clinics throughout
Australia and New Zealand, as well as their relatives, re-
ferred because of suspicion of having a genetic syndrome
[29]. CRC tumours were obtained and tested for mismatch
repair deficiency. In a course of research setting, ACCFR
participants with a mismatch deficient tumour were then
tested for germline mutations in the mismatch repair genes.
ACCFR participants and their family members were offered
the chance to have predictive genetic testing through their
nearest Family Cancer Clinic (FCC).
For this study, individuals were identified through the
ACCFR database according to the following criteria:
 Member of a family identified as carrying a mutation
in one of the following MMR genes: MLH1, MSH2,
MSH6 or PMS2
 Underwent genetic testing and received results for
LS either independently or after being offered results
by the ACCFR, no more than 10 years ago
 No personal history of CRC
 Aged 18 – 70 years
 Australian resident
Ethics approval was obtained through The University
of Melbourne Human Ethics Sub-Committee. Based on
the above criteria, over 300 ACCFR participants were
eligible to be approached about the study. Forty-three
individuals from separate families were selected based on
their MMR mutation status, with equal numbers of posi-
tive and negative genetic test results sampled. Each eligible
individual was sent a participant information and consent
form and followed up by phone to discuss whether or not
they wished to participate. Interviews were arranged at a
time and place convenient to the participant. Written in-
formed consent was obtained on the day of the interview.
Data collection continued until saturation of the main
themes was determined.
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Data Collection
Thirty-three interviews were conducted, predominantly
in participant’s homes in both rural and metropolitan
regions in the states of Victoria and Queensland. Data
collection consisted of an audio-recorded, semi-structured
interview on the topic of genetic testing for LS. Interviews
lasted between 60 and 90 min. General themes included:
cancer experience, genetic counselling experience, com-
munication around genetic test result, and screening
behaviours following genetic testing. The interviews were
transcribed verbatim and all identifying details were re-
moved from the transcripts.
Data analysis
NVivo 10 software was utilised to manage and code the
interview data [30]. Transcripts were read multiple times
and coded into the themes identified. A comparative
method of coding and analysis was conducted, and dis-
parities were discussed until consensus was met. Non-
carriers were analysed separately from the carriers in
order to determine how each group utilised the knowledge
of their genetic status to inform their risk management
practices, and how they found the process of organising
their screening. Additionally, female carriers were ana-
lysed in relation to their knowledge and decision-making
regarding risk management for GC.
Results
Of the 33 participants interviewed, 16 (48%) had tested
negatively (non-carriers) and 17 (52%) had tested posi-
tively (carriers) for a mutation in one of the MMR genes.
General characteristics of the sample are reported in
Table 1. All participant names presented in this paper
are pseudonyms.
Non-carriers – CRC risk management
Seven of the 16 non-carriers (44%) reported continu-
ing with colonoscopies since receiving a negative
genetic test result, either biennially or sporadically
(Tables 2 and 3). Five of these non-carriers (31%)
were having surveillance colonoscopies due to a personal
history of polyps (quotes 1 and 2). As illustrated by
Patrick, most of these non-carriers with a personal history
of polyps found reassurance in their continued colonos-
copies. They understood that although their genetic status
placed them at population risk of CRC, their history of
polyps required them to have ongoing surveillance. How-
ever, for one non-carrier (Ella), the ongoing detection of
polyps negated the potential reassurance of a negative
genetic test result.
Only two non-carriers (13%) were having screening
colonoscopies at the time of interview (quotes 3 and 4).
Jean recalled conflicting recommendations, noting that
the FCC suggested that she have a colonoscopy every 5-
10 years, but the gastroenterologist she was working
with at the time recommended biennial colonoscopies
based on her family history. Greg’s reported recommen-
dation from his gastroenterologist was also based on his
family history of CRC, as well as the fact that he has
Barrett’s syndrome, a known precursor to oesophageal
cancer. However, the current standard screening in indi-
viduals with Barrett’s syndrome is regular gastroscopies,
not colonoscopies [31]. Greg was also having FOBTs as
part of population-based CRC screening.
Of the seven non-carriers who reported not having any
form of CRC screening (56%), all were younger than 50
years of age at the time of interview. Only one of these
non-carriers could recall that he had been recommended
to have FOBTs from age 50 as per population CRC
screening guidelines (quote 5). The other six non-carriers
not enrolled in regular CRC screening could all recall
being told that they were considered to be at population
risk, but none of them knew at what age population-based
screening commences or what procedure is involved
(quotes 6 and 7). Some of these non-carriers recalled
that their genetic results disclosure session was brief,
with very little information on what they should do
regarding CRC screening (quotes 8 and 9).
Table 1 Participant characteristics
Characteristics Number (%) n = 33
Sex
Male 15 (45)
Female 18 (55)
Age at interview (years) 48 (mean)
Years since testing 5.4 (mean), 2 weeks – 10 years (range)
Mutation status
Positive (carrier) 17 (51)
Negative (non-carrier) 16 (49)
Relatives diagnosed with CRC 2 (mean)
Table 2 Non-carriers – reported CRC risk management
recommendations and what participants do in practice (n= 16)
Clinical recommendation In practice
Can’t recall (8) Population screening (2)
No current CRC screening (6)
Population screening (1) No current CRC screening (1)
Biennial colonoscopy (5) Biennial colonoscopy (2)
Biennial colonoscopy and population
screening (1)
Sporadic colonoscopies and population
screening (2)
Conflicting (2) Biennial colonoscopy (1)
Sporadic colonoscopies and population
screening (1)
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Two of the non-carriers who were no longer having
screening colonoscopies spoke about their difficulty in
accepting their non-carrier status (quotes 10 and 11). Prior
to testing, both had lived for several years as though they
were at high risk, perceiving that they would almost defin-
itely develop CRC. Meagan had been tested 4.5 years previ-
ously and spoke retrospectively about her initial struggle to
change her risk perception from high to population risk.
Michael had received his genetic test result only 2 weeks
previously and was still in the midst of accepting his popu-
lation risk status. Following testing, non-carriers described
having to adapt to not only a change of mindset, but also a
new identity, with CRC no longer being their “thing”.
Overall, non-carriers expressed a range of responses to
their test results. Some complied with their gastroenterolo-
gist’s recommendation for ongoing screening colonoscopies
due to their family history, despite no longer requiring that
level of screening. This provides evidence that for at least
some gastroenterologists, a negative genetic test result does
not override a family history. Those who were not having
regular screening colonoscopies understood that they were
at population risk, but were not aware of the recommended
screening for their risk level. There was evidence that for
some, adjustment to a reduced risk of CRC can take time.
Carriers – CRC risk management
All carriers recalled being recommended to have regu-
lar screening colonoscopies. Fifteen of the 17 carriers
(88%) reported having annual or 18 monthly colonoscopies
(Tables 4 and 5). Three of these carriers received conflicting
recommendations from the FCC and their gastroenterolo-
gist about how frequently they should be screening, and
reported following the advice of their gastroenterologist
(quote 12). The majority of carriers spoke about their
Table 3 Quotes from non-carriers – CRC risk management
Quote no. Participant Quote
1. Patrick (48, tested 2.5 years ago) I’ve always had polyps, I normally have a colonoscopy every two years now…Obviously it’s hereditary,
but because I’ve had the gene test done, well I’m no different to the normal person in the street I suppose.
2. Ella (50, tested 6.5 years ago) I have to have colonoscopies regardless because I have continued sort of polyps, so I’ve always believed
that they’re gonna find another gene so I have never completely let myself off the hook.
3. Jean (63, tested 6.5 years ago) The Doctor (Gastroenterologist) that I was working for at the time suggested I have it every two years…
I think they (FCC) said five to ten years actually…He said well that’s up to you, but I would like to see
you do it every two years…It’s awful, but I’d much rather do all of this to make sure I’m screened and
there’s nothing there…I haven’t got the gene but…I’m not scientifically trained enough to know what
the odds are or anything like that.
4. Greg (65, tested 6 years ago) I’ve got Barrett’s syndrome…When I was found not to have the gene [for Lynch syndrome] they said
you can have it every two years now the colonoscopy, but I’ve got to have the gastroscopy every
two years for sure…Because of the family history and the Barrett’s syndrome and all of that sort of
stuff…I have them at the same time.
5. Michael (41, tested 2 weeks ago) A doctor [at the FCC] came in and was explaining that their best practice understanding is you do a
faecal occult blood test every two years once you hit fifty, which I’m happy to do.
6. Paula (32, tested 3 years ago) Because my risk is still there but just the same as the normal person, then the normal screenings…
I can’t really remember in terms of colonoscopies and stuff, you know starting age…That’s probably
something that I can actually do a bit of homework on and find out roughly when I should be having
a bit of a think about it.
7. Andrew (38, tested 4 years ago) I remember them saying that even though I don’t have the gene, I’m still in the general population’s
risk level…Whether I wasn’t listening enough or haven’t read enough of the information they gave me
but I guess I’m not entirely sure as to what that means in terms of the recommendation would be for
my own future. I guess I’m like the average person, how often, what sort of check-ups should I have?
Should I have one of the FOB whatever they call its?
8. Alan (41, tested 4 years ago) Oh I guess someone who goes there and finds out a positive result probably needs a little bit more of
discussion about the consequences and what that might mean in their life. Someone who gets a negative
one, I just remember it being pretty short and sharp and congratulations you’re back in the normal
population, and you know, walk out.
9. Kay (44, tested 5 years ago) I get the feeling that they didn’t say much because otherwise I would have been probably, if they had
have suggested still being screened I probably would have been doing that so I think that they probably
didn’t say anything. They just said that we haven’t got the gene.
10. Meagan (33, tested 4.5 years ago) You’re always living as if you were going to get cancer, the inevitable. It was a bit hard to change the
mindset of you’re not going to or you know you’ve got the same chance as the general population…
Just to go, okay, it’s not inevitable.
11. Michael (41, tested 2 weeks ago) I got it in my head that I was going to die at thirty-six and not see my son grow up…What also dawned
upon me was that suddenly I’m now part of the normal population, that bowel cancer is not something
that I carry with me anymore, and I’m still getting used to that idea…You almost become protective of
bowel cancer, it’s like it’s your thing…Now it’s no longer that, and it’s kind of nice.
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dislike of the colonoscopy procedure, in particular the
preparation involved. However, all those who regularly
screened expressed faith in the relationship between
screening and CRC risk reduction (quotes 13 and 14).
Two carriers (12%) reported having colonoscopies spor-
adically. Matt discussed his dislike of the colonoscopy pro-
cedure, which put him off having them on a regular basis
(quote 15). Fred reported he wasn’t having regular colon-
oscopies due to a poor relationship with his previous doc-
tor (quote 16). He was asked if he would be more likely to
have regular colonoscopies if they were organised on his
behalf, but he didn’t think that would make much differ-
ence. However, he was hopeful to begin screening more
regularly given his increased comfort with his current
doctor. Despite not undertaking regular screening, Matt
believed his risk of developing CRC was high and placed it
at 90% (quote 17). In contrast, Fred did not perceive his risk
of developing cancer to be any higher than the average per-
son, which fits with his perception that CRC risk increases
with age in LS individuals (quote 18). However, rather than
focusing solely on CRC, Fred viewed cancer as a single dis-
ease of which everyone is at risk. He also expressed uncer-
tainty about the value of the genetic test, suggesting that
not enough is known about it yet to be able to place indi-
viduals at increased risk. Additionally, neither Matt nor
Fred expressed faith in the procedure’s ability to reduce
their risk of developing CRC.
These excerpts demonstrate that in order to adhere to
screening recommendations, carriers need to believe they
are at increased risk of CRC due to their LS mutation
status, be able to tolerate the procedure, and have faith
in screening as a means of risk reduction as well as
early detection.
Carriers – GC risk management
Female carriers (n = 9) were asked about their GC screen-
ing and risk management behaviours (Tables 6 and 7).
Seven (78%) could recall a discussion with the FCC re-
garding their gynaecological cancer risk, three of whom
subsequently had a prophylactic hysterectomy and
BSO, and four of whom were having annual pelvic ultra-
sounds (quote 19). Of the four who had not had surgery,
but were having annual pelvic ultrasounds, two were not
aware of prophylactic hysterectomy and BSO as a GC risk
management option (quote 20). Linda noted she recently
attended a workshop on LS, and was questioning the effect-
iveness of GC screening and planned to have a discussion
with her gynaecologist. Of the other two female carriers
who reported having annual pelvic ultrasounds, one hoped
to have children in the near future (quote 21), and one
didn’t think the surgery was warranted while she was
healthy (quote 22).
Two (22%) female carriers could not recall ever having
a discussion around GC screening and risk management
(quotes 23 and 24). Amy had learnt about the associated
risk of GC through her sister, also a carrier, and then at
Table 4 Carriers – reported CRC risk management
recommendations and what participants do in practice (n = 17)
Clinical recommendation In practice
Conflicting (3) 18 monthly (2)
Annual (1)
Annual (13) Annual (12)
Sporadic (1)
Biennial (1) Sporadic (1)
Table 5 Quotes from carriers – CRC risk management
Quote no. Participant Quote
12. Amy (32, tested
8 years ago)
I think it was a bit conflicting, you know some say every second year up until the age of thirty I think it was, but
I’ve been having annual for as long as I can remember. So yeah that seems to be a little bit grey that area – some
say annually, some say every second year.
13. Linda (47, tested
10 years ago)
I mean I hate having them, but you know you just go oh well, it’s locked in. I know what I need to do for that day.
14. Eve (52, tested
1.5 years ago)
Never having had a polyp and then this last time there was a polyp I go, okay, that’s why I do it…Cause I need to
have the polyp to create the cancer…Reassuring, that’s right. That’s why I’m doing it, to get it out
15. Matt (37, tested
10 years ago)
I don’t enjoy doing it. I’ve always asked is there any other way of doing it, can I try anything else and they say, nuh,
this is it…I’ve missed it a couple of times, I just don’t respond…I just feel uncomfortable doing it.
16. Fred (55, tested
4.5 years ago)
They said to do it every two years, and yet I’ve taken five years. As I said to you, I’ll probably do it more now because
I’m getting older and because the doctor I’m with now, I’m more comfortable with him.
17. Matt (37, tested
10 years ago)
My dad keeps on drumming in my head to keep on getting tested, but I don’t know. It’s not going to solve
anything…The wife, she’s cracked it a few times at me because sometimes I haven’t gone. I said if it’s gonna get me,
it’s gonna get me…[How would you describe your chance of getting bowel cancer now?] High. Ninety percent.
They (colonoscopies) can’t prevent it. It’s just getting it at an early stage, it’s not going to stop it by coming.
18. Fred (55, tested
4.5 years ago)
No risk at all, because I just don’t think we know enough about it to be able to say that you’re at higher risk. Someone
could have a test and say you haven’t got the gene, but then they develop another form of cancer from something else…
If I had a colonoscopy tomorrow, didn’t have one for two years but then in between that two years had cancer, why
didn’t it get picked up? What brings it out at what stage?
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a recent LS workshop. Gaby didn’t learn about the associ-
ated risk of GC until she was diagnosed with endometrial
cancer. Both Amy and Gaby adhered to CRC screening
recommendations.
These insights demonstrate the perception of lack of
clarity available to some women about the risk of GC
for carriers, and the options for managing that risk. Of
particular concern were women closely following the
recommendations given to them for managing their high
CRC risk, while being unaware of their increased GC risk.
Gaby expressed it was unfair that she was diagnosed with
endometrial cancer, given her perception that she was
following all the appropriate risk management recommen-
dations. In addition to Amy and Gaby not being offered
any advice about GC, the remaining seven women recalled
three different sets of recommendations (Table 5).
Discussion
This study provides novel qualitative insights into the
transition between receiving genetic risk information for
LS and enacting risk management procedures, exploring
why some non-carriers continue to have unnecessary
invasive screening, and why some carriers do not follow
screening recommendations.
Our study was able to explore some of the reasoning
behind continued screening in the non-carrier group,
which other studies have not been able to determine
[27, 28, 32]. The five non-carriers (31%) with a personal
history of polyps felt reassured by their continued
screening practice to monitor their polyps, and almost
all of them understood that their genetic status did not
increase their risk of developing CRC. Only one of these
non-carriers, Ella, expressed uncertainty about the value
of the predictive genetic test, considering that a yet-to-be-
discovered gene was potentially responsible for the devel-
opment of her polyps. Aktan-Collan et al. [33] report that
non-carriers who doubt the validity of predictive genetic
testing for LS are more likely to have continued colonos-
copies, although they also speculate that medical reasons
could be a reason behind continued colonoscopies. Our
qualitative data illustrates that although disbelief in the
value of the genetic test was present, the main reason
behind continued colonoscopies in this group of non-
carriers was indeed medical. In fact, only two (13%) non-
carriers were having screening colonoscopies, and both
were following a recommendation to do so from their
gastroenterologist. Given that we collected information on
self-reported screening, it is possible that these two non-
carriers were having colonoscopies for medical reasons
not mentioned here. That said, knowledge about heredi-
tary cancer syndromes and their associated surveillance
procedures has been shown to be insufficient amongst
non-genetic health professionals, including gastroenterol-
ogists [34–37], and clinician recommendation has been
found to be a highly influential factor in the uptake of
Table 6 Female carriers – reported GC risk management
recommendations and what participants do in practice (n = 9)
Clinical recommendation In practice
Can’t recall (2) No current GC screening (2)
Annual pelvic ultrasound (2) Annual pelvic ultrasound (2)
Prophylactic hysterectomy
and BSO (3)
Prophylactic hysterectomy
and BSO (3)
Annual pelvic ultrasound, prophylactic
hysterectomy and BSO (2)
Annual pelvic ultrasound (2)
Table 7 Quotes from carriers – GC risk management
Quote no. Participant Quote
19. Adele (41, tested
4 years ago)
We talked about future surgeries and my options as what way to go next, it was all done straight away…She sort of said,
go away and think about it…So within three months I was in hospital having a full hysterectomy…For me, prevention is
better than cure.
20. Linda (47, tested
10 years ago)
They (the FCC) actually gave me a contact for a Gynaecologist that dealt with people with Lynch syndrome…They said
the colonoscopies would be every year and the endometrial sort of stuff would be probably once a year as well…From
that Lynch workshop we had the other day, they were sort of saying that maybe that’s not the best sort of screening
[for gynaecological cancers]…I’ll probably have to ask the gynaecologist to make sure that well is this the best screening,
or what do they recommend?
21. Caroline (31, tested
8 years ago)
[Do you think about it a lot?] More so the issue of the uterus cancer, not having kids and cause I haven’t sort of necessarily
found someone, that probably gets to me a little bit more than anything.
22. Shelly (65, tested
1.5 years ago)
I remember them telling me that, the specialist, that he may suggest that I have a hysterectomy…So I went and sure as
eggs, that’s what he suggested and I can see that he’s seeing it from the medical [point of view], but I was healthy. I said,
are my ovaries healthy? He said yes. So I don’t want to do that, and that was over a year ago.
23. Amy (32, tested
8 years ago)
When I found out my sister was having the ultrasound I said to her, why are you having that? I’m pretty sure in that initial
meeting when we all found out that we were carrying it, it was just the colonoscopy that was the screening. There were
no other options at that stage…But I will be looking into that.
24. Gaby (51, tested
10 years ago)
[The risk of endometrial cancer] wasn’t mentioned, I don’t think so. I don’t remember. It might have been but I don’t
remember…I was bleeding a lot…I went and saw my Oncologist, he said it’s all related. I thought it was more so the
breast and ovarian cancer was linked with the bowel, didn’t know about the endometrial. So yeah that was a little bit
of a piss me off because I try to keep up with everything. It is what it is, can’t change it, just deal with it.
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colonoscopies [38]. It is therefore also possible that these
gastroenterologists were not knowledgeable enough about
LS to understand that ongoing screening colonoscopies
are not recommended for asymptomatic non-carriers,
even if they have a strong family history of CRC.
As demonstrated by Meagan and Michael, receiving a
negative mutation result can take time to adjust to, espe-
cially for individuals who have been living for many years
as though they were at high risk. Their comments provide
qualitative insight into non-carrier cancer-specific distress,
which has been shown to steadily decrease in the years
following predictive genetic testing for LS [27, 33, 39, 40].
Our findings exemplify that although cancer-specific
distress and anxiety generally decreases in the years follow-
ing predictive genetic testing, non-carriers can experience
long-term uncertainty regarding CRC risk management.
A number of non-carriers could not recall what they had
been advised regarding population-based CRC screening,
and although these non-carriers understood that they were
now considered to be at population risk, they were unclear
about what population CRC screening entailed and at what
age it commenced. This could be due to recall bias, as the
only non-carrier who was able to recall this information
was Michael. However, given that there was poor know-
ledge and that genetic result disclosure sessions were
reportedly brief in many instances, it is also worth con-
sidering investing more time in supporting the psycho-
logical and behavioural adaptation of individuals who
receive a negative result following predictive genetic
testing for LS.
All carriers received a clinical recommendation to have a
colonoscopy every 1-2 years. The minority who received
conflicting recommendations were not confused or
deterred from having regular screening. Our data sug-
gests that in order to adhere to screening recommen-
dations, carriers need to believe they are at increased
risk of developing CRC, be able to tolerate the procedure,
and believe in the efficacy of colonoscopy screening. One
of the two carriers screening sporadically lacked all three
of these conditions (Fred), and the other (Matt) lacked
two. It is not clear what led these men to have reduced
faith in colonoscopy for the prevention of CRC, however
this finding is consistent with previous studies on adher-
ence to regular colonoscopies, which note that the num-
ber of physical and psychological barriers to screening is
related to more sporadic screening [41–44]. The qualita-
tive perspective provided by our study also suggests that
some barriers may be more influential than others. For
example, Fred declared that even if his screening was
organised on his behalf it probably wouldn’t change his
screening practice. Rather, it was his poor relationship
with his doctor, his disbelief in being at increased risk, and
his view that colonoscopies would not reduce his risk of
developing CRC which influenced his non-adherence to
screening recommendations. Likewise, it is possible that
Matt’s lack of faith in the procedure’s ability to reduce his
risk has more influence on his screening practice than his
dislike for the procedure.
The majority of female carriers (78%) reported some
form of GC risk management, either by the way of surgery
(prophylactic hysterectomy and BSO) or annual screening
(pelvic ultrasound). Of concern, two (22%) female carriers
could not recall receiving GC risk management advice
(Gaby and Amy). Both of these female carriers were having
annual colonoscopies, highlighting a lack of communica-
tion about their GC risk. Additionally, although Shelly
reported having annual pelvic ultrasounds, she was of
the belief that a prophylactic hysterectomy and BSO wasn’t
warranted while her ovaries appeared healthy. Given that to
date no benefit has been shown for ovarian cancer
screening, and there is little evidence for the benefit of
pelvic ultrasounds for endometrial cancer screening,
Shelly’s comments raise the question of whether she
has been accurately informed that the only effective
intervention to reduce her risk of GC is prophylactic
surgery. Likewise, although Linda and Ruth were hav-
ing annual pelvic ultrasounds, they were not aware of
prophylactic hysterectomy and BSO as a risk manage-
ment option.
The limited number of studies looking at why adherence
to GC risk management is generally low have reported
that female carriers are less aware about their associated
risk of GC, and therefore less likely to adopt appropriate
risk management behaviours [22, 42, 45]. The only reason
for not adhering to GC risk management recommenda-
tions in our study sample was lack of awareness. Given
the high risk of developing GC and the lack of effective
screening, it is essential that female carriers are made
aware of their increased risk of GC and are fully informed
about their risk management options.
Conclusion
Findings from this study highlight that although the
majority of carriers and non-carriers of LS tend to
adapt to appropriate CRC and GC risk management in
the long term, there is evidence of a hierarchy of confi-
dence in information provided to those receiving pre-
dictive genetic test results. Participants expressed most
confidence about the use of regular colonoscopies to
manage CRC risk for carriers, and less confidence about
the risk and management of GC for female carriers, with
very few non-carriers able to recall advice regarding
population screening. Despite the higher levels of confi-
dence in colonoscopy for carriers, we found evidence of
non-adherence to colonoscopy screening. Evidence pre-
sented here suggests that to address this, further elabor-
ation of the effectiveness of colonoscopies in reducing the
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risk of CRC and the meaning of predictive genetic test
results will be required for some.
While the relatively small sample size limits the gener-
alisability of findings, saturation of the main themes was
evident, suggesting the potential for reproducible find-
ings in future studies. A larger sample size and quanti-
tative methodology would allow for individuals to be
grouped based on characteristics such as age and time
since testing.
Practice implications
Our findings, around how genetic risk information for
LS translates to risk management behaviours, have
implications for the communication of information be-
tween specialist cancer genetic services, the patient, and
the clinicians responsible for their ongoing management.
Non-carriers:
 Invest more time in result disclosure sessions, ensuring
that non-carriers are aware of the recommended
screening for their risk level
 In the letter to managing clinicians, explain that a
strong family history is not of significance to
individuals with a negative mutation result, and that
ongoing screening colonoscopies are no longer
required for those who are asymptomatic
Carriers:
 Offer additional genetic counselling to carriers not
screening regularly to explore the reasoning behind
their non-adherence to screening recommendations
 Ensure that female carriers and their managing
clinicians are aware of the associated risk of GC and
appropriate risk management options
 Communicate with carriers and their managing
clinicians when risk management recommendations
are updated
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